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international assistance and cooperation for access to essential medicines
Emily A. Mok
abstract
Access to essential medicines is a critical problem that plagues many developing countries. With a daunting number of domestic constraints — technologically, economically, and otherwise — developing countries are faced with a steep uphill battle to meet
the human rights obligation of providing essential medicines immediately. To meet
these challenges, the international human rights obligations of international assistance
                  
access to essential medicines. This article seeks to highlight and expand upon the current understanding of international assistance and cooperation for access to essential
                       
              
introduction
The problem of access to medicines unduly burdens developing countries around the world. It has been estimated that “infectious diseases kill
over 14 million people each year, nine out of ten of whom live in the
developing world.”1 Children and young adults in Africa and Southeast
Asia bear a heavy burden in infectious diseases, where half of the deaths
among this group are due to six treatable diseases — HIV/AIDS (14%
of deaths), acute respiratory syndrome (11%), diarrheal diseases (11%),
malaria (8%), measles (6%), and TB (2%).2 Despite the existence of
effective medicines, millions of people will continue to suffer and die
needlessly from these and other life-threatening conditions because they
cannot access the necessary treatments. It has been estimated that as
many as two billion people (one-third of the world’s population) lacks
access to such essential medicines.3
The stark inequities faced by such populations, notably those suffering
from HIV/AIDS, have highlighted the acute need for international assistance and cooperation in support of their plight. Novel institutions have
been established to provide assistance, such as UNAIDS; the Global
Fund to Fight AIDS, Tuberculosis and Malaria; and the U.S. President’s
Emergency Plan for AIDS Relief (PEPFAR). Bold declarations of
cooperation have emerged in a variety of international policy fora. For
example, World Trade Organization (WTO) member states issued a for 
           
of Intellectual Property Rights (TRIPS) “can and should be interpreted
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human rights law. The claim of “access to medicines”
has been used by developing countries, activists, intergovernmental organizations, academics, and others
in a variety of contexts, but their use of the phrase
in relation to human rights does not always imply the
same meaning. Quite often the phrase refers to treatment access for life-threatening diseases that affect
Over the past decade, dramatic increases in access critical public health needs, or such treatment access
             !"#$ in cases of emergency, with a direct reference to the
7
   
have been achieved; however, the general problem * ! +  0
of access to medicines “for all” still persists.5 In the medicines.”7 In other instances, the phrase includes
search for a solution, various scholars and health the category of “neglected diseases,” that is, diseases
practitioners have turned to human rights in an effort for which a lack of attention has been paid toward
to understand how greater access to medicines could research and development for appropriate treatbe established through a rights-based approach in ments.8 There has also been increasing reference to
developing countries. A growing body of work has treatments for the chronic diseases and conditions,
         - such as pain management and cancer.9
ative of the right to health, outlines its component
human rights obligations, considers its relationship The Universal Declaration of Human Rights (UDHR),
with the competing interests of intellectual prop- adopted in 1948 by the UN, proclaims in Article 25.1
erty rights, and analyzes its justiciability in domestic that “everyone has the right to a standard of living
courts.6 There has been limited attention, however, adequate for the health of himself and of his family,
to the extraterritorial obligations of developed coun- including food, clothing, housing and medical care.”10
tries on this issue. Hence, one might ask: What The term “medical care” as used by the UDHR is
international assistance and cooperation obligations understood to include medicines — such as drugs
do developed countries hold in relation to access to and vaccines.11 Another key human rights source
medicines, and how should it affect their policies and including access to medicines is the International
practices on this issue? Developed countries have a Covenant on Economic, Social and Cultural Rights
critical role in access to medicines efforts; yet, their (ICESCR), which was adopted by the UN in 1966
support and response to this issue has been weaker and holds the status of an international treaty that is
than needed and, in some cases, counterproductive in legally binding upon the 192 member states of the
UN. According to Article 12.1 of the ICESCR, states
the policy measures taken.
must “recognize the right of everyone to the enjoyThis article seeks to develop the current understand- ment of the highest attainable standard of physical
ing on international assistance and cooperation for and mental health.”12 Furthermore, in attaining the
   &       '          >  @J@7   KL&L
international assistance and cooperation for access        X   Y 
to medicines by reviewing the derivation of access for “the prevention, treatment and control of epi             - demic, endemic, occupational and other diseases”
ments on international assistance and cooperation and “the creation of conditions which would assure
in international human rights law. The article then to all medical service and medical attention in the
builds upon this knowledge to develop a set of stan- event of sickness.”13
dards to guide developed country actions and policies
To assist states with their implementation of the
in domestic and international fora.
ICESCR, the Committee on Economic, Social and
@      Z@J@[         access to medicines as a human right
   KL   @J@7\  
In order to establish conceptual clarity on the inter- Comment No. 14.14 For example, the CESCR has
national assistance and cooperation obligations of interpreted Article 12 to indicate that the provision of
states, it is necessary to understand the scope of   >]    *!+

access to medicines entitlements under international Programme on Essential Drugs” is a core obligation

and implemented in a manner supportive of WTO
members’ right to protect public health, and in particular, to promote access to medicines for all.”4 This
     
 ibilities,” such as compulsory licensing and parallel
importation, to address public health concerns.
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of states under the right to health.15 The World Health
+  0  Z*!+[        
“those that satisfy the priority health care needs of the
population.”16 To help guide countries in their selection and coverage of medicines under national policies,
WHO develops a biennial “model list” of essential
medicines.17 WHO recommends that these medicines
“be available within the context of functioning health
systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate
information, and at a price the individual and the
community can afford.”18 In recognition of differing
national health needs, WHO intends for “the concept
    ] ' '  '
to many different situations; exactly which medicines
are regarded as essential medicines remains a national
responsibility.”19
The distinction between essential medicines —
which are a core obligation — and other medicines
is important for the explication of state obligations.
Brigit Toebes explains that core obligations must be
guaranteed “immediately” and “under any circumstances.”20 Given that such obligations are considered
to “encompass the essence of the right,” it is critical to ensure its existence within a state or else the
 ^      &21 This contrasts with
other non-core obligations of the right to health that
are subject to “progressive realization,” which only
require “deliberate, concrete and targeted” steps in
an expeditious and effective manner.22 Such non-core
obligations would include the other medicines that are
not considered “essential” or have yet to exist. Hence,
as Paul Hunt and Rajat Khosla conclude, “while a
state is required to progressively realize access to non
essential medicines, it has a core obligation of immediate effect to make essential medicines available and
accessible throughout its jurisdiction.”23
The core obligation of access to essential medicines,
however, can often pose a serious problem for developing countries. In such countries, the large populations
of impoverished and disease-stricken individuals who
lack basic necessities (such as food, water, and shelter)
already cause a major strain on government resources,
among other domestic economic and social concerns.
In recognition of the disparate realities amongst the
countries, General Comment 14 states:
For the avoidance of any doubt, the
Committee wishes to emphasize that

it is particularly incumbent on States
parties and other actors in a position
to assist, to provide “international
assistance and cooperation, especially
economic and technical” which enable
        
and other obligations.24
This comment emphasizes that human rights duties are
not limited to domestic borders, but also encompass
those that fall outside state jurisdiction. If an industrialized nation were to disregard this, the nation could
'     `{     
legal obligations towards the right to health.”25
The remainder of this paper focuses largely on the
core obligation of access to essential medicines in
order to explicate developed countries’ international
assistance and cooperation duties. While it will touch
upon the broader concept of access to medicines, in
the interest of space, a detailed exploration of these
various dimensions would require a separate study.
The following section elaborates on how internation      
 ' 
  
under international human rights law.
international assistance and
cooperation according to international
human rights law
The state obligation to provide international assistance and cooperation has long been an area of
debate among academics. While some might hold fast
to the notion of state sovereignty and the idea that
states hold human rights obligations only in relation
to their own citizens, the impacts of globalization
 Y         

boundaries. In addition, some argue that state obligations of international assistance and cooperation
were intended by the drafters of international human
rights laws, as the obligation can be found in the key
documents, including Articles 1(3), 55 and 56 of the
UN Charter; Articles 22 and 28 of the UDHR; and
Articles 2(1), 11(1), 11(2), 15(4), 22 and 23 of the
ICESCR. Sigrun Skogly believes that, because these
' 
     Y   0   
rarely been invoked, there is a need to “rediscover or
uncover these obligations” from the body of international human rights law.26
For example, an important source of international
assistance and cooperation is found in Article 2(1)
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of the ICESCR, which requires “[e]ach State Party
to the present Covenant undertakes to take steps,
individually and through international assistance and
cooperation, especially economic and technical, to the
maximum of its available resources.”27 The “elusive
and complex” nature of this statement, which can
be attributed to diplomatic negotiations, was noted
'Y @J@   
  \  
Comment No. 3 on “[t]he nature of states parties’
obligations.”28 General Comment No. 3 explained
that those who drafted the ICESCR intended that
the statement, “to the maximum of its available
resources,” apply not only to the resources within a
state, but also to “those available from the international community through international cooperation
and assistance.”29

obligations of international
assistance and cooperation in relation
to access to medicines

In light of the above summary, it is apparent that
developed countries hold obligations of international assistance and cooperation for access to essential
medicines. Yet, despite the allusions to these topics in international human rights law, there contin  '     '  Y      
international roles and responsibilities that should
be met by states extraterritorially. This issue has
prompted numerous authoritative, but nonbinding, interpretative statements that aim to clarify and
expand upon references to essential medicines in
international agreements, especially given emerging global health trends and issues. Such statements
include the UN Committee on Economic, Social
Yet, in what manner should developed countries assist and Cultural Rights General Comment 14, the UN
and cooperate? To address this question, the tripar- Commission on Human Rights Resolution 2003/29,
      '   Z   >   > World Health Assembly Resolution WHA55.14,
   >    [  '    '   the UN Millennium Development Goals, Montreal
on the developed country duty of international assis- Statement on Essential Medicines as a Human Right,
tance and cooperation in greater detail.30 The duty WTO Declaration on the Agreement on Tradeto respect, which has been called a “classic” human Related Aspects of Intellectual Property Rights and
rights obligation, refers to the requirement that states Public Health, and the reports of the UN Special
“avoid measures that hinder or prevent the enjoyment Rapporteur on the Right to Health.36
of … rights in another state.”31 Such measures would
include a state’s foreign policies and any aspects that The guidance offered by these sources is synthesized
might interfere with the realization of rights outside of to develop a single, more coherent set of internathe state. The duty to protect requires that states take tional standards for developed countries on access
account of human rights in their actions as members to essential medicines. The theme of international
of international organizations, as well as when entering assistance and cooperation as a duty, a theme found
into bilateral and multilateral agreements.32 It also calls across almost all interpretative guidance on access
upon states to “take measures to prevent non-state to medicines, presents a critical set of standards for
entities under their jurisdiction from interfering with developed countries. By applying the comprehensive
the enjoyment of the … rights abroad.”33 Such non- guidelines listed in the CESCR’s General Comment
state entities include private corporations that reside No. 14 as a foundation, the discussion below details
within their national jurisdiction but operate interna- the international assistance and cooperation stantionally or have an impact on other states, and mea- dards that developed countries must address.
sures to prevent them can take the form of domestic
         & Y 
'    '         X To respect access to essential medicines in other countries,
positive steps by facilitating, providing, and promot- and to prevent others (that is, third parties) from
37
ing human rights in other states.34 This particular duty violating this right
has been considered controversial, given its emphasis This is a critical standard which obligates states “to
on positive state action in other countries, but is gain- refrain from interfering directly or indirectly” with
ing acceptance in the human rights community as a a developing country’s efforts to achieve access to
“secondary or subsidiary obligation [that] … applies essential medicines.38 At the same time, it asks indusif the domestic state for reasons beyond its control trialized nations to “protect” access to essential medi    >  >       cines in developing countries by preventing third
when “measures taken to respect and protect are not parties (such as pharmaceuticals or other countries)
  &35
that may interfere with this fundamental component
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of the right to health.39 Such guidance is critical in
understanding industrialized nation obligations in
regards to the WTO TRIPS Agreement.

extreme urgency” and that such cases can be understood to include “HIV/AIDS, tuberculosis, malaria
and other epidemics.”45

According to the Doha Declaration on TRIPS and
Public Health, developing countries have the right
      '     
 
their public health needs. First, countries have “the
right to grant compulsory licenses and the freedom
to determine the grounds upon which such licenses
are granted.”40 Second, countries’ “practices relating
to parallel importation cannot be challenged under
the WTO dispute settlement system [and] … each
Member is free to establish its own regime [for the
use of parallel importation] … without challenge.”41
Hence, industrialized nations should refrain from
interfering in developing country activities to apply
compulsory licensing or parallel importation for
access to essential medicines. Historically, the US has
placed countries that attempt to exercise compulsory
licensing on the US Trade Representative Watch List,
known as the Special 301. This practice would effectively pressure US trading partners, especially developing countries, into acting in accordance with US
preferences in order to gain or maintain a favorable
trading position with the US. Furthermore, industrialized nations should prevent others (for example,
pharmaceutical companies) from interfering in such
activities as well.

To ensure that access to essential medicines is granted
due attention in international agreements and to
consider the development of further legal instruments 46

To facilitate access to essential medicines in other
countries, whenever possible, and to provide the necessary
aid in times of emergency 42
In recognition of the limitations of developing
  7 '          ' 

(for example, access to essential medicines) to their
populations, it follows that an associated international assistance and cooperation duty calls upon
  0 
       
in those countries. Furthermore, in situations of
emergency, it is emphasized that developed countries
have a responsibility to contribute to “the maximum
of [their] capacities.”43 The CESCR notes that other
countries’ emergencies are a “collective responsibility” at an international level because “some diseases
are easily transmissible beyond the frontiers of a
State.”44 Though General Comment No. 14 does not
 Y   ^      
    gency, other international guidance has stated that
countries have “the right to determine what constitutes a national emergency or other circumstances of

Industrialized nations are urged “to develop and
implement national strategies,” including legal measures, that “safeguard or promote” access to essential
medicines.47 Though many States have acceded to
numerous international agreements recognizing obligations to assist and cooperate in the provision of
access to medicines, such agreements are often not
    
 >   > 
ignored and often relegated to rhetoric. This is a standard that requires greater attention and evaluation.

To ensure that no international agreement or policy
adversely impacts upon access to essential medicines 48
As parties to numerous current international agreements, as well as potential future agreements, states
need to ensure that no adverse measures within the
agreements will hinder access to essential medicines.
Furthermore, states should never apply restrictions
on the supply of essential medicines in another state
as a tool of political or economic pressure – such
as embargoes, political or theological ideology, or
other similar measures.49 This has been an issue for
a number of developed countries and their tendency
for corporate protectionism through the creation of
“TRIPS-plus” provisions (that is, measures that go
beyond what is required by TRIPS) in bilateral and
regional trade agreements with developing countries.

To ensure (by way of membership) that the actions of
international organizations take due account of access
to essential medicines 50
International organizations, such as the World Health
Organization, the World Trade Organization, and the
World Bank, play critical roles in setting policy and
    
       
access to medicines in developing countries. States
can use their membership status within these international organizations to ensure that access to essential
medicines is properly accounted for in the activities
of such organizations. For instance, the WTO’s activities in setting minimum standards for the protection
of intellectual property rights (that is, Agreement
on Trade-Related Aspects of Intellectual Property

volume 12, no. 1
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acknowledge such standards. A review of these various aforementioned documents revealed an array of
scattered agreements and declarations that pertain to
state obligations, but also a general consistency in the
expectations for international assistance and cooperation that are addressed most comprehensively by
General Comment No. 14. Despite the general consistency in the international expectations of states,
                  as illustrated in the synthesized set of international
of responsibilities in access to essential medicines by
standards, the scattered nature of these standards
other actors 51
amongst the various documents can allow states to
Though states possess primary accountability for the conveniently “miss” or disregard certain obligations.
right to health, the General Comment also empha- Hence, for the purposes of implementation, it would
sizes that “all members of society” possess certain be best to present a single, coherent set of standards
“responsibilities towards the realization of the right from which states can report on or be criticized
to health.”52 In the case of access to essential medi- against and to promote comprehensive implementacines, other societal actors involved include inter- tion by states.
governmental and nongovernmental organizations,
health professionals, civil society organizations, and The array of authoritative guidance indicates a delibprivate industry. The CESCR notes that in order for erate movement by the international order to crys       '  >   tallize the elusive access to medicines obligations
an obligation to “provide an environment which of developed countries. The acceptance of these
facilitates the discharge of these responsibilities.”53
 
    >  ^ >      For example, the US has a duty to create an equal cant challenges due to its heavy basis on socioecoopportunity for health professionals to participate nomic rights. As Paul Hunt has noted, “[a]lthough
on government advisory committees pertaining to the right to health is [a] fundamental human right,
essential medicines policies, which is a privilege that with the same international legal status as freedom of
the pharmaceutical industry currently enjoys.
religion or the right to a fair trial, [it] is not as widely
recognized as these other civil and political rights.”55
  
>              
conclusion
policy concerns (for example, international trade
This article seeks to highlight and clarify the inter- and development) may be granted special preference
national assistance and cooperation obligations of over access to medicines because of their impact on
developed countries in relation to access to essen- national economic or security interests.
tial medicines. While developing countries hold the
“primary obligation” for ensuring access to essential To some degree, it would appear that developed
medicines within their jurisdiction, there are times countries are supporting access to medicines in other
when they might not have the necessary resources countries through their growing involvement in globavailable to support such an effort.54 This dilemma al health programs providing treatment. Such prohas prompted attention into the international obliga- grams include multilateral initiatives (for example, the
tions of states to support access to essential medi- Global Fund) and bilateral programs (for example,
cines. While international obligations in human rights the UK Department for International Development
          Y   Z  > [DFID] and PEPFAR). Recent history has shown,
through foreign aid), there are also duties to respect however, that developed countries still need to
and protect the realization of access to essential med- remain cognizant of their international assistance
icines in other states.
and cooperation obligations to respect, protect, and
     ^   X    

It is undoubtedly the case that international assis- organizations and in adopting multilateral, regional,
tance and cooperation standards for access to essen- or bilateral agreements. For example, the selective
tial medicines exist, but the wide array of authorita- activities of bilateral global health programs have
tive documentation from which they had to be drawn sometimes shown a preference for recipient coun  X           X
   tries that provide a national security interest. In addi  [            
countries’ access to medicines. Member states have
worked to ensure that TRIPS address the issue of
access to medicines through a subsequent clarifying
statement known as the Declaration on the TRIPS
agreement and public health.
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tion, bilateral programs have not always upheld nondiscrimination principles by neglecting vulnerable
populations requiring treatment, such as sex workers and men who have sex with men. States need to
also develop ways to incorporate their international
human rights commitments into their domestic and
foreign policy strategies. This would allow states to
account for international human rights interests in all
government sectors and is especially important for
access to medicines. For example, the UK recently
launched a government policy strategy known as
“Health is Global,” which aims to take the health of
people beyond its borders into account.56
$       ^Y   lating and incentivizing the pharmaceutical industry
to pay greater attention to the medicines that are
needed by developing countries. In terms of existing
medicines, the participation of corporations in drug
donation and discount programs are a critical factor
in alleviating the problem of medicines affordability
in developing countries. Neglected diseases, however,
will require the developed countries to implement
incentive schemes that would attract the pharmaceutical industry to invest their R&D resources for new
or improved medicines. The current approaches have
been weaker than needed, and states can do much to
establish the enabling environment that would encourage industry participation in access to medicines.
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